공고 • Jun 04
Pure Biologics S.A., Annual General Meeting, Jun 29, 2026 Pure Biologics S.A., Annual General Meeting, Jun 29, 2026, at 11:00 Central European Standard Time. New Risk • Dec 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 118% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.6m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-zł18m). Earnings have declined by 8.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (zł33.2m market cap, or US$9.13m). 공고 • Nov 11
Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025 Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025 공고 • Aug 21
Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025 Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025 New Risk • Jun 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Negative equity (-zł13m). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł28.6m market cap, or US$7.64m). Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding). New Risk • Apr 04
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: zł38.3m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł10m free cash flow). Negative equity (-zł5.0m). Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (zł38.3m market cap, or US$9.80m). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). 공고 • Jun 05
Pure Biologics S.A., Annual General Meeting, Jun 28, 2024 Pure Biologics S.A., Annual General Meeting, Jun 28, 2024. New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 48% per year over the past 5 years. Revenue is less than US$1m (zł109k revenue, or US$28k). Market cap is less than US$10m (zł22.3m market cap, or US$5.66m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Reported Earnings • Nov 19
Third quarter 2023 earnings released: zł2.36 loss per share (vs zł2.85 loss in 3Q 2022) Third quarter 2023 results: zł2.36 loss per share. Net loss: zł7.60m (loss widened 18% from 3Q 2022). Reported Earnings • Sep 03
Second quarter 2023 earnings released Second quarter 2023 results: Net loss: zł9.92m (loss widened 75% from 2Q 2022). Reported Earnings • May 21
First quarter 2023 earnings released: zł2.29 loss per share (vs zł2.82 loss in 1Q 2022) First quarter 2023 results: zł2.29 loss per share. Net loss: zł7.04m (loss widened 11% from 1Q 2022). 공고 • May 09
Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023 Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023, at 12:00 Central European Standard Time. Reported Earnings • Sep 18
Second quarter 2022 earnings released: zł2.51 loss per share (vs zł1.63 loss in 2Q 2021) Second quarter 2022 results: zł2.51 loss per share (further deteriorated from zł1.63 loss in 2Q 2021). Revenue: zł6.41m (up zł6.34m from 2Q 2021). Net loss: zł5.66m (loss widened 55% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Reported Earnings • Apr 02
Full year 2021 earnings released: zł5.22 loss per share (vs zł7.11 loss in FY 2020) Full year 2021 results: zł5.22 loss per share. Revenue: zł18.0m (up zł17.5m from FY 2020). Net loss: zł11.8m (flat on FY 2020). Over the next year, revenue is expected to shrink by 97% compared to a 155% growth forecast for the pharmaceuticals industry in Poland. Reported Earnings • Nov 18
Third quarter 2021 earnings released: zł2.02 loss per share (vs zł1.60 loss in 3Q 2020) Third quarter 2021 results: Net loss: zł4.28m (loss widened 62% from 3Q 2020). Reported Earnings • Sep 15
Second quarter 2021 earnings released: zł1.63 loss per share (vs zł1.59 loss in 2Q 2020) Second quarter 2021 results: Net loss: zł3.66m (loss widened 39% from 2Q 2020). Is New 90 Day High Low • Jan 11
New 90-day high: zł131 The company is up 45% from its price of zł90.00 on 13 October 2020. The Polish market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 32% over the same period. Reported Earnings • Nov 16
Third quarter 2020 earnings released: zł1.60 loss per share Third quarter 2020 results: Net loss: zł2.64m (loss widened 180% from 3Q 2019). Is New 90 Day High Low • Oct 29
New 90-day low: zł73.80 The company is down 26% from its price of zł100.00 on 30 July 2020. The Polish market is down 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. Is New 90 Day High Low • Sep 24
New 90-day low: zł91.00 The company is down 10.0% from its price of zł101 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 44% over the same period. 
